Yuko Kanbayashi

497 citations
46 papers · 356 indexed · h-index 11
Topics
Chemotherapy-related skin toxicity (9 papers)Cancer Treatment and Pharmacology (8 papers)Neutropenia and Cancer Infections (7 papers)

In The Last Decade

Yuko Kanbayashi

43 papers receiving 350 citations

Peers

Yuko Kanbayashi
Comparison fields: 5 of 77
  • Oncology 176
  • Dermatology 83
  • Epidemiology 58
  • Hematology 58
  • Surgery 47
Replace Valentí Puig‐Diví with:
Valentí Puig‐Diví Spain
Sameh Trabelsi Tunisia
Julien Carvelli France
Don Bredle United States
Ismet Aydogdu Türkiye
V. Minotti Italy
Irvin M. Cohen United States
Xiao-ning Zhong China
Thomas Greco United States
Antonietta Coppola Italy
Yuko Kanbayashi relative to Valentí Puig‐Diví Spain Valentí Puig‐Diví's profile →
Citations per field
00.5×2.5×
Valentí Puig‐Diví · 1×
Citations per year

Countries citing papers authored by Yuko Kanbayashi

Since Specialization
Citations

This map shows the geographic impact of Yuko Kanbayashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuko Kanbayashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuko Kanbayashi more than expected).

Fields of papers citing papers by Yuko Kanbayashi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuko Kanbayashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuko Kanbayashi. The network helps show where Yuko Kanbayashi may publish in the future.

Co-authorship network of co-authors of Yuko Kanbayashi

This figure shows the co-authorship network connecting the top 25 collaborators of Yuko Kanbayashi. A scholar is included among the top collaborators of Yuko Kanbayashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuko Kanbayashi. Yuko Kanbayashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 2
4 0
5 2
6 4
7 1
8 5
9 3
10 12
11 21
12 3
13 11
14 8
15 7
16 3
17 16
18 50
19 5
20 9

About Yuko Kanbayashi

Yuko Kanbayashi is a scholar working on Dermatology, Anesthesiology and Pain Medicine and Oncology, having authored 46 papers that have together received 356 indexed citations. Recurring topics across this work include Chemotherapy-related skin toxicity (9 papers), Cancer Treatment and Pharmacology (8 papers) and Neutropenia and Cancer Infections (7 papers). The work is most often cited by research in Dermatology (83 citations), Oncology (176 citations) and Anesthesiology and Pain Medicine (35 citations). Yuko Kanbayashi has collaborated with scholars based in Japan, United States and New Zealand. Frequent co-authors include Toyoshi Hosokawa, Masafumi Taniwaki, Tetsuya Taguchi, Tatsuya Takagi, Kousuke Okamoto, Takeshi Ishikawa, Eigo Otsuji, Hideyuki Konishi, Koichi Takayama and Koichi Sakaguchi. Their work appears in journals such as PLoS ONE, Scientific Reports and Journal of Antimicrobial Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026